C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding C4 Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 113 | 119 | +6 |
| Shares | 34.5M | 35.9M | +1.40M (+4.1%) |
| Value | $1.54B | $1.15B | −$387.8M (−25.1%) |
New holders (22)
Institutions that held C4 Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (16)
Institutions that held C4 Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Point72 Asset Management, L.P. | 200,000 | $8.94M |
| First Trust Advisors LP | 86,952 | $3.88M |
| P.A.W. Capital Corp | 40,000 | $1.79M |
| Gilder Gagnon Howe & Co LLC | 39,506 | $1.76M |
| Prudential Financial Inc | 23,270 | $1.04M |
| Two Sigma Investments, LP | 21,073 | $942.0K |
| Acuta Capital Partners, LLC | 21,000 | $938.0K |
| Blueshift Asset Management, LLC | 6,719 | $300.0K |
| Man Group plc | 6,423 | $287.0K |
| Meristem Family Wealth, LLC | 6,000 | $268.0K |
| Russell Investments Group, Ltd. | 5,056 | $225.0K |
| O'Shaughnessy Asset Management, LLC | 1,037 | $46.0K |
| TCI Wealth Advisors, Inc. | 106 | $5.00K |
| Parallel Advisors, LLC | 106 | $5.00K |
| Signaturefd, LLC | 16 | $1.00K |
| Quadrant Capital Group LLC | 4 | $0 |